154 related articles for article (PubMed ID: 15285925)
1. Progression rates of colorectal cancer by Dukes' stage in a high-risk group: analysis of selective colorectal cancer screening.
Wong JM; Yen MF; Lai MS; Duffy SW; Smith RA; Chen TH
Cancer J; 2004; 10(3):160-9. PubMed ID: 15285925
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
Mandel JS; Church TR; Ederer F; Bond JH
J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of investigations for colorectal carcinoma in symptomatic patients.
Kalra L; Hamlyn AN
Postgrad Med J; 1988 Sep; 64(755):666-8. PubMed ID: 3251216
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
7. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the Serum Level of Carcinoembryonic Antigen and Prolactin with Different Stages of Colorectal Carcinoma According to Dukes' Staging.
Rahman MR; Sheikh SH; Lima IJ; Islam MR; Faisal M; Islam MS; Faruk MO; Jalal MT
Mymensingh Med J; 2016 Jan; 25(1):61-5. PubMed ID: 26931251
[TBL] [Abstract][Full Text] [Related]
9. [A systematic review of worldwide natural history models of colorectal cancer: classification, transition rate and a recommendation for developing Chinese population-specific model].
Li ZF; Huang HY; Shi JF; Guo CG; Zou SM; Liu CC; Wang Y; Wang L; Zhu SL; Wu SL; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):253-260. PubMed ID: 28231677
[No Abstract] [Full Text] [Related]
10. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with colorectal cancer detected by a community screening program.
Rae LC; Gibberd RW
Med J Aust; 2000 Jan; 172(1):13-5. PubMed ID: 10682009
[TBL] [Abstract][Full Text] [Related]
12. Different distribution of Dukes' stage between proximal and distal colorectal cancer.
Ikeda Y; Akagi K; Kinoshita J; Abe T; Miyazaki M; Mori M; Sugimachi K
Hepatogastroenterology; 2002; 49(48):1535-7. PubMed ID: 12397728
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
14. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
15. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited.
De Quay N; Cerottini JP; Albe X; Saraga E; Givel JC; Caplin S
Eur J Surg; 1999 Jun; 165(6):588-92. PubMed ID: 10433145
[TBL] [Abstract][Full Text] [Related]
16. How many lymph nodes should be examined in Dukes' B colorectal cancer? Determination on the basis of cumulative survival rate.
Yoshimatsu K; Ishibashi K; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Hepatogastroenterology; 2005; 52(66):1703-6. PubMed ID: 16334761
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Shiratori Y
Gastroenterology; 2005 Aug; 129(2):422-8. PubMed ID: 16083699
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
19. Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study.
Mukai M; Ito I; Mukoyama S; Tajima T; Saito Y; Nakasaki H; Sato S; Makuuchi H
Oncol Rep; 2003; 10(4):927-34. PubMed ID: 12792747
[TBL] [Abstract][Full Text] [Related]
20. Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends.
McClements PL; Madurasinghe V; Thomson CS; Fraser CG; Carey FA; Steele RJ; Lawrence G; Brewster DH
Cancer Epidemiol; 2012 Aug; 36(4):e232-42. PubMed ID: 22425027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
